CFM
BDTX icon

Catalyst Funds Management’s Black Diamond Therapeutics BDTX Stock Holding History

Catalyst Funds Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,200
Closed -$32.4K – 677
2026
Q1 		$32.4K Buy
+15,200
New +$36.2K 0.01% 560
2025
Q4 		– Sell
-27,800
Closed -$105K – 354
2025
Q3 		$105K Buy
27,800
+9,300
+50% +$27.2K 0.02% 459
2025
Q2 		$45.9K Buy
+18,500
New +$35.7K 0.01% 378

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Catalyst Funds Management's BDTX Position: Q2 2026 in Review

Catalyst Funds Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 15,200 shares — an estimated $32.4K sold.

Catalyst Funds Management first reported a position in BDTX in Q2 2025 and held it in 3 quarters. The position peaked at $105K in Q3 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Catalyst Funds Management reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 15,200 Black Diamond Therapeutics shares in Q2 2026, an estimated $32.4K.
  • Catalyst Funds Management first reported a position in Black Diamond Therapeutics in Q2 2025 and held it in 3 quarters.
  • Catalyst Funds Management's Black Diamond Therapeutics position peaked at $105K in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.